Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON50120
NL-OMON50120
Completed
Not Applicable

Assess safety of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers - MABs therapy m.3243A>G mutation carriers

Medisch Universitair Ziekenhuis Maastricht0 sites15 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsmitochondrial myopathymitochondrial muscular disease10028302

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
mitochondrial myopathy
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
15
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • •Adult carriers of \>40% m.3243A\>G mutation in muscle

Exclusion Criteria

  • •\- Use of anti\-coagulants, anti\-thrombotics and other medication influencing
  • •coagulation
  • •\- Have a weekly alcohol intake of \>\= 35 units (men) or \>\= 24 units (women)
  • •\- Current history of drug abuse
  • •\- Deficient immune system or autoimmune disease
  • •\- Significant concurrent illness
  • •\- Ongoing participation in other clinical trials
  • •\- Major surgery within 4 weeks of the visit
  • •\- Vaccination within 4 weeks of the visit
  • •\- Pregnant or lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials

Withdrawn
Not Applicable
Intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriersmitochondrial myopathymitochondrial muscular disease10028302
NL-OMON42959Erasmus MC, Universitair Medisch Centrum Rotterdam5
Not yet recruiting
Phase 2
Assess effect and safety of intra-arterial autologous mesoangioblasts administration to the upper arm of m.3243A>G mutation carriers
NL-OMON55910Medisch Universitair Ziekenhuis Maastricht20
Completed
Phase 1
MABs Therapy m.3243A>G Mutation CarriersMitochondrial Myopathies
NCT05063721Maastricht University6
Terminated
Phase 1
Patient-Derived Stem Cell Therapy for Diabetic Kidney DiseaseDiabetic Kidney DiseaseDiabetic NephropathiesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Chronic Kidney DiseaseDiabetic Nephropathy Type 2Kidney FailureKidney Insufficiency
NCT03840343Mayo Clinic2
Not yet recruiting
Not Applicable
Evaluation of intra-venous mesenchymal stem cells for the treatment of small joint osteoarthritisOsteoarthritisMusculoskeletal - Osteoarthritis
ACTRN12619000883112Melbourne Stem Cell Centre10